🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07496580
Starting soon Not applicable

Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia

NCT07496580 · tracked via the Priya Life Science China tracker
Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase
Not applicable
Started
2026-03-01
Last updated
2026-03-27

Condition(s) studied

Functional DyspepsiaElectroacupuncture

Investigational drug(s) / intervention(s)

Electroacupuncture (Local Acupoints)Electroacupuncture (Distal Acupoints)Sham Electroacupuncture (Control)

Electroacupuncture (Local Acupoints): Participants assigned to this intervention will receive electroacupuncture at local abdominal acupoints, including bilateral Shangwan (CV13), Zhongwan (CV12), Xiawan (CV10), Liangmen (ST21), and Tianshu (ST25). Sterile disposable acupuncture needles (0.30 × 40 mm) will be inserted vertically by licensed acupuncturists with at least three years of clinical experience to a depth of approximately 20-30 mm to elicit the Deqi sensation (such as soreness, numbness, distension, or heaviness). Two pairs of acupoints (Shangwan-Zhongwan and left Liangmen-right Liangmen) will be connected to an SDZ-V electroacupuncture device. Electrical stimulation will be applied at a frequency of 5 Hz, with current intensity adjusted to the participant's tolerance. Each treatment session will last 30 minutes and will be administered twice weekly for 3 weeks (6 sessions in total).

Electroacupuncture (Distal Acupoints): Participants in this group will receive electroacupuncture at distal limb acupoints, including bilateral Zusanli (ST36), Shangjuxu (ST37), Xiajuxu (ST39), and Yinlingquan (SP9). Sterile disposable acupuncture needles (0.30 × 40 mm) will be inserted by trained acupuncturists to achieve the Deqi sensation. Electrical stimulation will be applied by connecting bilateral Zusanli (ST36) and Xiajuxu (ST39) to an SDZ-V electroacupuncture device. The stimulation frequency will be set at 5 Hz, and the current intensity will be adjusted according to the participant's tolerance. Each session will last 30 minutes, administered twice weekly for 3 weeks (6 sessions in total).

Sham Electroacupuncture (Control): Participants in the control group will receive acupuncture at the same acupoints as the electroacupuncture groups using identical needling procedures to achieve the Deqi sensation. However, the needles will be connected to a specially designed sham electroacupuncture device that appears identical to the active SDZ-V electroacupuncture device but does not deliver electrical stimulation. Each treatment session will last 30 minutes and will be administered twice weekly for 3 weeks (6 sessions in total).

Study summary

Functional dyspepsia (FD) is a common disorder that causes stomach discomfort, such as fullness or pain after eating, without any visible structural disease. Acupuncture is often used to manage these symptoms. This study aims to evaluate the safety and effectiveness of electroacupuncture-a form of acupuncture that uses gentle electrical stimulation-for treating functional dyspepsia. Specifically, the trial will compare the benefits of applying electroacupuncture to points on the abdomen (local points) versus points on the arms and legs (distal points), alongside a control group receiving a sham (inactive) treatment. The goal is to determine the most effective acupuncture strategy for improving patients' digestive symptoms and overall quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Participants who meet the Rome IV diagnostic criteria for functional dyspepsia (FD). * Age 18 to 80 years, male or female. * Chinese patients with a normal upper gastrointestinal endoscopy within the past 1 year, or judged by a gastroenterologist with more than 3 years of clinical experience to have no structural disease that explains the symptoms. * Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: * Functional dyspepsia symptoms caused by severe or malignant diseases (e.g., liver cirrhosis, heart failure, or gastrointestinal tumors). * Helicobacter pylori infection, defined as a positive urea breath test or positive Hp test on endoscopy. * History of gastrointestinal surgery (except minimally invasive procedures such as laparoscopy). * Presence of a permanent or temporary cardiac pacemaker or use of external/temporary pacing support. * Use of medications that may affect dyspepsia symptoms within 2 weeks prior to enrollment, including antisecretory drugs, antacids, prokinetic agents, digestive enzymes, nonsteroidal anti-inflammatory drugs, antidepressants, or traditional Chinese medicine for FD. * Conditions that may make participation difficult, such as severe mental or physical illness, dementia, or illiteracy. * Severe coagulation disorders. * Acupuncture treatment for gastrointestinal diseases within the past 1 month. * Participation in another clinical trial within the past 2 months. * Drug abuse or alcohol abuse. * Pregnant or breastfeeding women.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Hangzhou First People's Hospital Hangzhou Zhejiang
Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine Hangzhou Zhejiang
The First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang
The Third Affiliated Hospital of Zhejiang Chinese Medicinal University Hangzhou Zhejiang

More The Third Affiliated hospital of Zhejiang Chinese Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07496580 on ClinicalTrials.gov ↗ ← All trials in China